Summary:
Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a review of the Proficiency Testing (PT) data report (CASPER report 155), graded results from the College of American Pathologists (CAP), and an interview with the testing person, the laboratory failed to successfully participate in PT for the Specialty of Hematology and the analyte Hemoglobin. The laboratory had unsatisfactory scores for the third event in 2022 and the second event of 2023. See D2130 D2130 HEMATOLOGY CFR(s): 493.851(f) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a review of the Proficiency Testing (PT) data report (CASPER report 155), graded results from College of American Pathologists (CAP), and an interview with the testing person, the laboratory failed to successfully participate in PT for the Specialty of Hematology and the analyte Hemoglobin. The laboratory had unsatisfactory scores for the third event in 2022 and the second event of 2023. Findings include: 1. Specialty of Hematology a. CAP 2022 Event 3 = 0% b. CAP 2023 Event 2 = 50% 2. Hemoglobin a. CAP 2022 Event 3 = 0% b. CAP 2023 Event 2 = 0% 3. An interview with the testing person on September 6, 2023 at 1:30 PM confirmed the laboratory failed to achieve satisfactory performance for the Specialty of Hematology and the analyte Hemoglobin for the third event in 2023and the second event of 2023. -- 2 of 2 --